First Clinical Data of MT103 (MEDI-538), a CD19-specific BiTE(R), to Be Presented at the 11th Congress of the European Hematology Association
Thursday June 1, 3:09 am ET
MÃœNCHEN, GERMANY--(MARKET WIRE)--Jun 1, 2006 -- Carlsbad, CA - June 1, 2006 - Micromet, Inc. (NasdaqNM:MITI - News) announced today that preliminary data from an ongoing phase 1 trial on MT103 will be presented at the 11th Congress of the European Hematology Association (EHA). The abstract has been selected by the EHA for oral forum presentation scheduled for June 17, 2006, at 11:15 AM CET / 05:15 AM EST by Dr. Ralf Bargou, the principal investigator of the trial from the University of Wuerzburg, Germany. In addition, data will be presented as a poster on June 16 at 5:45 PM CET / 11:45 AM EST.
The congress will be held on June 15-18, 2006 at the Amsterdam RAI Convention Centre, The Netherlands.
A download of the presentation will be available on Micromet's website at www.micromet-inc.com. |
